Key result
Engineered immunosuppressive dendritic cells protect against cardiac remodelling in preclinical models.
No change to clinical practice; leaves open translation of engineered dendritic cells to human heart failure trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied Cardiac remodelling. Engineered immunosuppressive dendritic cells (iCDC) vs. Sham, VecDC, or disease model alone was evaluated. Engineered immunosuppressive dendritic cells protect against cardiac remodelling in preclinical models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: